What records are connected here?
- Evidence lanes
- 3
- Source years
- 8
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsMetabolic and weight
Dasiglucagon is a lab-made 29-amino-acid analogue of glucagon, the hormone that raises blood sugar. It is the active ingredient in Zegalogue, which FDA approved in 2021 for severe low blood sugar in people with diabetes aged 6 and older.1,2 In three randomized, placebo-controlled trials described in the label, blood sugar recovered faster with dasiglucagon than with placebo; in the largest, of 170 adults, the median time was 10 minutes versus 40.1 Drugs@FDA now lists both Zegalogue products as discontinued.2
| What it is | A synthetic glucagon analogue of 29 amino acids that activates glucagon receptors in the liver, according to the Zegalogue label.1 |
|---|---|
| FDA status | FDA-approved, but discontinued. Drugs@FDA lists Zegalogue, NDA 214231, with an original approval date of March 22, 2021, and lists both of its products as discontinued.2 |
| Human evidence | Three randomized, double-blind, placebo-controlled trials in people with type 1 diabetes, two in adults and one in children aged 6 to 17, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Dasiglucagon is a synthetic analogue of the hormone glucagon, made of 29 amino acids, according to the label.1
In the United States it is the active ingredient of Zegalogue, approved under NDA 214231, according to Drugs@FDA.2
The label states that dasiglucagon activates glucagon receptors in the liver, which breaks down stored glycogen and releases glucose into the blood. It needs liver glycogen stores to work.1
The label describes three randomized, double-blind, placebo-controlled trials in people with type 1 diabetes whose blood sugar was lowered under controlled conditions. The main outcome was the time for blood sugar to recover.1
In Trial A, 170 adults were randomized to dasiglucagon, placebo or glucagon. Median recovery took 10 minutes with dasiglucagon, 40 minutes with placebo and 12 minutes with glucagon, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes, but Drugs@FDA lists both Zegalogue products under application NDA 214231 as discontinued. The application’s original approval date is March 22, 2021.2
The Zegalogue label cited here (DailyMed SPL version 3, published June 17, 2026) states that it is indicated for severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.1
The label has no boxed warning. It states that dasiglucagon must not be used in people with pheochromocytoma, because it may trigger a large rise in blood pressure, and warns that it can cause later low blood sugar in people with insulinoma.1
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list dasiglucagon.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Dasiglucagon is not among them.4,5
How it performs in real emergencies: the trials described in the label lowered blood sugar under controlled conditions and had no formal statistical comparison with glucagon.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Dasiglucagon: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Dasiglucagon are a bounded selection, not every registration or paper about Dasiglucagon. For the years before Dasiglucagon was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Dasiglucagon as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Dasiglucagon in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Zegalogue for severe low blood sugar; discontinued. Three randomized, placebo-controlled trials described in the label found faster blood sugar recovery with dasiglucagon than with placebo. Dasiglucagon is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Zegalogue for severe low blood sugar; discontinued. Three randomized, placebo-controlled trials described in the label found faster blood sugar recovery with dasiglucagon than with placebo. Dasiglucagon is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.↗Source date November 9, 2026Literature metadata · added November 16, 2026
Dasiglucagon Hydrochloride.↗Source date November 9, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT03941236↗Source date August 3, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
16 of 16 selected trial records include at least one phase value; 16 of 16 include a status value in the retained structured contract.
2 of 2 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT02916251 at 2026-11-16T01:42:39.027Z. Its registry update date was 2017-04-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03216226 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-04, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon.
2 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span April 21, 2017 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 33906916 in Diabetes care as Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-27 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 33998648 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2021-07-22 (day precision). PeptideScanner associated the retained record with the identity slug dasiglucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03941236 at 2026-11-16T01:42:39.027Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04172441 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Regulatory
The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04764968 at 2026-11-16T01:42:39.027Z. Its registry update date was 2022-09-07, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03667053 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026